Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Tumors 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × Homoharringtonine × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT01844869 2015-01-30

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡